Intracellular Th is a drug manufacturers-specialty & generic business based in the US. Intracellular Th shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intracellular Th employs 512 staff and has a trailing 12-month revenue of around $138.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $46.53 |
|---|---|
| 52-week range | $34.43 - $66.00 |
| 50-day moving average | $52.31 |
| 200-day moving average | $53.05 |
| Wall St. target price | $70.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.61 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $46.53 from 2022-09-30
| 1 week (2022-09-23) | 6.94% |
|---|---|
| 1 month (2022-09-02) | -9.84% |
| 3 months (2022-07-01) | -15.66% |
| 6 months (2022-04-01) | -25.77% |
| 1 year (2021-10-01) | 20.98% |
|---|---|
| 2 years (2020-10-02) | 95.42% |
| 3 years (2019-10-02) | 491.98% |
| 5 years (2017-10-02) | 200.00% |
| Revenue TTM | $138.5 million |
|---|---|
| Gross profit TTM | $-13,077,085 |
| Return on assets TTM | -28.16% |
| Return on equity TTM | -50.38% |
| Profit margin | -232.11% |
| Book value | $7.65 |
| Market capitalisation | $4.1 billion |
TTM: trailing 12 months
We're not expecting Intracellular Th to pay a dividend over the next 12 months.
Over the last 12 months, Intracellular Th's shares have ranged in value from as little as $34.43 up to $66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intracellular Th's is 1.1878. This would suggest that Intracellular Th's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.